If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Genetic Test Requisition Form is required.  If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic. Please send any available clinical information with Requisition Form.

Targeted mutation analysis is available for family members when familial mutation is known (see Test Code: FMLIS).

This test is a full gene sequence analysis of the IDUA gene that sequences the entire protein coding regions (exons) as well as splice sites (exon-intron junctions).

Presence of a pathogenic variant in both alleles of the IDUA gene is known to cause mucopolysaccharidosis type I (MPS I). MPS I is an autosomal recessive, progressive genetic disorder that can cause a widely variable disease severity that are classified into two groups - Severe MPS I (also known as Hurler syndrome) and Attenuated MPS I (also known as Hurler-Scheie syndrome or Scheie syndrome). Individuals with severe MPS I typically start manifesting symptoms within the first year of life, which those with attenuated MPS I typically develop symptoms between ages 3 to 10 years. Common clinical features of MPS I include coarse facial features, recurrent upper respiratory and ear infections early in life, inguinal or umbilical hernia, hepatosplenomegaly, gibbus deformity, limited joint range of motion, and corneal clouding. Individuals with MPS I have deficient activity of the lysosomal enzyme alpha-L-iduronidase, which can be detected in most tissue types including blood leukocytes, plasma, or cultured fibroblasts. Diagnosis of MPS I can be made by detecting presence of biallelic pathogenic variants in the IDUA gene by molecular genetic testing and/or detection of deficient alpha-L-iduronidase enzyme activity by enzyme activity testing.

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Genetic Test Requisition Form is required.  If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic. Please send any available clinical information with Requisition Form.

Targeted mutation analysis is available for family members when familial mutation is known (see Test Code: FMLIS).

This test is a full gene sequence analysis of the IDUA gene that sequences the entire protein coding regions (exons) as well as splice sites (exon-intron junctions).

Presence of a pathogenic variant in both alleles of the IDUA gene is known to cause mucopolysaccharidosis type I (MPS I). MPS I is an autosomal recessive, progressive genetic disorder that can cause a widely variable disease severity that are classified into two groups - Severe MPS I (also known as Hurler syndrome) and Attenuated MPS I (also known as Hurler-Scheie syndrome or Scheie syndrome). Individuals with severe MPS I typically start manifesting symptoms within the first year of life, which those with attenuated MPS I typically develop symptoms between ages 3 to 10 years. Common clinical features of MPS I include coarse facial features, recurrent upper respiratory and ear infections early in life, inguinal or umbilical hernia, hepatosplenomegaly, gibbus deformity, limited joint range of motion, and corneal clouding. Individuals with MPS I have deficient activity of the lysosomal enzyme alpha-L-iduronidase, which can be detected in most tissue types including blood leukocytes, plasma, or cultured fibroblasts. Diagnosis of MPS I can be made by detecting presence of biallelic pathogenic variants in the IDUA gene by molecular genetic testing and/or detection of deficient alpha-L-iduronidase enzyme activity by enzyme activity testing.

This test is a full gene sequence analysis of the IDUA gene that sequences the entire protein coding regions (exons) as well as splice sites (exon-intron junctions).

Presence of a pathogenic variant in both alleles of the IDUA gene is known to cause mucopolysaccharidosis type I (MPS I). MPS I is an autosomal recessive, progressive genetic disorder that can cause a widely variable disease severity that are classified into two groups - Severe MPS I (also known as Hurler syndrome) and Attenuated MPS I (also known as Hurler-Scheie syndrome or Scheie syndrome). Individuals with severe MPS I typically start manifesting symptoms within the first year of life, which those with attenuated MPS I typically develop symptoms between ages 3 to 10 years. Common clinical features of MPS I include coarse facial features, recurrent upper respiratory and ear infections early in life, inguinal or umbilical hernia, hepatosplenomegaly, gibbus deformity, limited joint range of motion, and corneal clouding. Individuals with MPS I have deficient activity of the lysosomal enzyme alpha-L-iduronidase, which can be detected in most tissue types including blood leukocytes, plasma, or cultured fibroblasts. Diagnosis of MPS I can be made by detecting presence of biallelic pathogenic variants in the IDUA gene by molecular genetic testing and/or detection of deficient alpha-L-iduronidase enzyme activity by enzyme activity testing.

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Genetic Test Requisition Form is required.  If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic. Please send any available clinical information with Requisition Form.

Targeted mutation analysis is available for family members when familial mutation is known (see Test Code: FMLIS).

This test is a full gene sequence analysis of the IDUA gene that sequences the entire protein coding regions (exons) as well as splice sites (exon-intron junctions).

Presence of a pathogenic variant in both alleles of the IDUA gene is known to cause mucopolysaccharidosis type I (MPS I). MPS I is an autosomal recessive, progressive genetic disorder that can cause a widely variable disease severity that are classified into two groups - Severe MPS I (also known as Hurler syndrome) and Attenuated MPS I (also known as Hurler-Scheie syndrome or Scheie syndrome). Individuals with severe MPS I typically start manifesting symptoms within the first year of life, which those with attenuated MPS I typically develop symptoms between ages 3 to 10 years. Common clinical features of MPS I include coarse facial features, recurrent upper respiratory and ear infections early in life, inguinal or umbilical hernia, hepatosplenomegaly, gibbus deformity, limited joint range of motion, and corneal clouding. Individuals with MPS I have deficient activity of the lysosomal enzyme alpha-L-iduronidase, which can be detected in most tissue types including blood leukocytes, plasma, or cultured fibroblasts. Diagnosis of MPS I can be made by detecting presence of biallelic pathogenic variants in the IDUA gene by molecular genetic testing and/or detection of deficient alpha-L-iduronidase enzyme activity by enzyme activity testing.